<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Subjects with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and <z:mp ids='MP_0002871'>albuminuria</z:mp> are at risk for progressive diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The relative blood pressure lowering and antialbuminuric efficacy of angiotensin receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (ARB) vs. angiotensin-converting enzyme (ACE) inhibitor has not been well studied </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Forty-one ARB- and <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi>-naive T2DM subjects with <z:mp ids='MP_0002871'>albuminuria</z:mp> (&gt;30 mg/g <z:chebi fb="0" ids="16737">creatinine</z:chebi>) were given either 50 mg of <z:chebi fb="0" ids="6541">losartan</z:chebi> (ARB) or 20 mg of <z:chebi fb="0" ids="8713">quinapril</z:chebi> (<z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi>) (50% maximum dose) for 4 weeks, with a 4-week wash-out period in-between interventions in a crossover fashion </plain></SENT>
<SENT sid="3" pm="."><plain>The order of intervention was randomized </plain></SENT>
<SENT sid="4" pm="."><plain>The primary endpoint was the reduction of blood pressure and <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary endpoint was changes in plasma transforming growth factor beta (TGF-beta) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Among the 41 subjects, 66% were male </plain></SENT>
<SENT sid="7" pm="."><plain>The mean age (s.d.) was 52 (10) years, and duration of <z:mp ids='MP_0002055'>diabetes</z:mp> was 8 (14) years </plain></SENT>
<SENT sid="8" pm="."><plain>Blood pressure reduction (though not statistically significant) was similar on both interventions [systolic: <z:chebi fb="0" ids="6541">losartan</z:chebi> 3 (15) vs. <z:chebi fb="0" ids="8713">quinapril</z:chebi> 2 (13) mmHg, p = 0.52; diastolic: <z:chebi fb="0" ids="6541">losartan</z:chebi> 1 (9) vs. <z:chebi fb="0" ids="8713">quinapril</z:chebi> 2 (8) mmHg, p = 0.55] </plain></SENT>
<SENT sid="9" pm="."><plain>However, amelioration of <z:mp ids='MP_0002871'>albuminuria</z:mp> [mean (s.e.)] was significantly greater with <z:chebi fb="0" ids="6541">losartan</z:chebi> [<z:chebi fb="0" ids="6541">losartan</z:chebi> vs. <z:chebi fb="0" ids="8713">quinapril</z:chebi>: -93 (82) vs. -49 (65) mg/g, p = 0.02] </plain></SENT>
<SENT sid="10" pm="."><plain>There was no change in plasma TGF-beta levels [mean (s.d.)] on either treatment, <z:chebi fb="0" ids="6541">losartan</z:chebi> [before 12.1 (8.9) vs. after 11.9 (9.6) ng/ml, p = 0.68] and <z:chebi fb="0" ids="8713">quinapril</z:chebi> [11.1 (7.9) vs. 11.1 (7.8) ng/ml, p = 0.87) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: In Asian subjects with T2DM and <z:mp ids='MP_0002871'>albuminuria</z:mp>, 4 weeks of <z:chebi fb="0" ids="6541">losartan</z:chebi> therapy at 50 mg daily appeared to have greater antialbuminuric effect than 20 mg of <z:chebi fb="0" ids="8713">quinapril</z:chebi> </plain></SENT>
</text></document>